ISSN: 2462-3547



Endoscopic assessment and current topics of treatment of inflammatory bowel disease



Francisco Bosques-Padilla, Gastroenterology Unit, Hospital Universitario «Dr. José E. González», Universidad Autónoma de Nuevo León; Clinical Professor, Instituto Tecnológico y de Estudios Superiores de Monterrey (ITESM), Monterrey, N.L., Mexico
Jesús K. Yamamoto-Furusho , Inflammatory Bowel Disease Clinic, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, D.F., Mexico


Biosimilars are defined as biologic products that are highly similar to reference products, notwithstanding minor differences in clinically inactive components, with no clinically meaningful differences between the biologic product and the reference product in terms of safety profile, purity, and potency. Due to the high cost of innovator biologics, as well as an increase in the number of these products reaching patent expiry, the development of a process for approving biosimilar products has become a crucial regulatory issue in the USA.



Keywords: